Iran Press/ Iran News: In the unveiling ceremony of the first phase of the clinical trial of the 'Noora' COVID-19 vaccine, the head of Baqiyatallah University of Medical Sciences and conductor of the project, Hassan Abolghasemi, stated that there were strict standards to approve the vaccine.
He noted that the 'Noora' COVID-19 vaccine was made of a recombinant protein which has the least side effects and yields the best result.
He said the 'Noora' vaccine symbolizes Iran’s ability to produce biological vaccines.
"Despite the US, Iran shares all its scientific achievements with the world, he pointed.
Abolghasemi expressed hope that after clinical trials, one million doses of the Noora vaccine could be produced per month which could be increased up to three million doses per month.
214/221
Read More:
Iran, Russia negotiate to produce COVID-19 vaccine jointly
